MCH-1623 is a nucleoside analog-derived, RNA-dependent RNA polymerase (RdRP) inhibitor. MCH-1623 interferes with viral RNA synthesis and exhibits broad-spectrum antiviral activity. MCH-1623 effectively inhibits the replication of vesicular stomatitis virus (VSV), influenza A virus (H1N1-PR8), human coronavirus OC43, human metapneumovirus (HMPV) and respiratory syncytial virus (RSV). Administered via inhalation, MCH-1623 exerts significant in vivo activity in mice, reducing pulmonary viral load and IL-6 levels, alleviating pulmonary tissue erythema, and significantly improving the survival rate of mice infected with lethal influenza virus. MCH-1623 can be used to investigate the infection mechanisms of various RNA viruses and for antiviral drug research.
